文献速递造血干细胞移植与细胞治疗白血病

干扰素γ受体信号阻断上调的S100A9作为新型移植物抗宿主病抑制因子且不影响移植物抗白血病效应

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice.
PubMed 文献 · Blood · 2023-01-01

该研究在小鼠同种异体造血干细胞移植模型中发现,供者T细胞中IFNGR信号被阻断后S100A9表达上调,S100A9过表达或Ifngr1缺失的T细胞均可减轻GVHD而不损害GVL,重组S100A9蛋白及抗人IFNGRα中和抗体同样改善GVHD并减少T细胞向GVHD靶器官的迁移。

要点

  • 供者T细胞Ifngr1缺失或S100a9过表达可显著减轻小鼠GVHD而不影响GVL
  • 体内给予重组鼠S100A9蛋白可延长受体小鼠总生存期
  • 抗人IFNGRα中和抗体上调人T细胞S100A9并改善异种移植模型GVHD

核心结论

  • S100A9是受IFNGR信号抑制的下游分子,作为新型GVHD抑制因子发挥作用且不影响GVL。

研究设计与样本

  • 研究采用小鼠同种异体造血干细胞移植模型及异种人外周血单个核细胞移植模型。

主要发现

  • Ifngr1-/-和S100a9过表达T细胞均显著减轻GVHD而不损害GVL,并改变供者T细胞向GVHD靶器官的迁移。
  • 体内给予重组鼠S100A9蛋白延长受体小鼠总生存期。
  • 体内给予抗人IFNGRα中和抗体显著上调人T细胞S100A9表达并改善GVHD,减少人T细胞向GVHD靶器官迁移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for both malignant and nonmalignant hematologic disorders. However, graft-versus-host disease (GVHD) and malignant relapse limit its therapeutic success. We previously demonstrated that the blockade of interferon-gamma receptor (IFNGR) signaling in donor T cells resulted in a reduction in GVHD while preserving graft-versus-leukemia (GVL) effects. However, the underlying molecular mechanisms remain inconclusive. In this study, we found that S100A9 is a novel GVHD suppressor upregulated when IFNGR is blocked in T cells. Both Ifngr1-/- and S100a9-overexpressing T cells significantly reduced GVHD without compromising GVL, altering donor T-cell trafficking to GVHD target organs in our mouse model of allo-HSCT. In addition, in vivo administration of recombinant murine S100A9 proteins prolongs the overall survival of recipient mice. Furthermore, in vivo administration of anti-human IFNGRα neutralizing antibody (αhGR-Nab) significantly upregulates the expression of S100A9 in human T cells and improved GVHD in our mouse model of xenogeneic human peripheral blood mononuclear cell transplantation. Consistent with S100a9-overexpressing T cells in our allo-HSCT model, αhGR-Nab reduced human T-cell trafficking to the GVHD target organs. Taken together, S100A9, a downstream molecule suppressed by IFNGR signaling, functions as a novel GVHD suppressor without compromising GVL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kim S, Lim S, Kim B, et al. S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice. Blood. 2023. PMID: 36477272. doi:10.1182/blood.2021012687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。